SG11201705626QA - Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis - Google Patents

Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis

Info

Publication number
SG11201705626QA
SG11201705626QA SG11201705626QA SG11201705626QA SG11201705626QA SG 11201705626Q A SG11201705626Q A SG 11201705626QA SG 11201705626Q A SG11201705626Q A SG 11201705626QA SG 11201705626Q A SG11201705626Q A SG 11201705626QA SG 11201705626Q A SG11201705626Q A SG 11201705626QA
Authority
SG
Singapore
Prior art keywords
leishmaniasis
pyrazolo
treatment
pyrimidin
derivative
Prior art date
Application number
SG11201705626QA
Inventor
Timothy James Miles
Michael George Thomas
Original Assignee
Glaxosmithkline Ip Dev Ltd
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Univ Dundee filed Critical Glaxosmithkline Ip Dev Ltd
Publication of SG11201705626QA publication Critical patent/SG11201705626QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201705626QA 2015-01-23 2016-01-21 Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis SG11201705626QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382011 2015-01-23
PCT/EP2016/051240 WO2016116563A1 (en) 2015-01-23 2016-01-21 Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
SG11201705626QA true SG11201705626QA (en) 2017-08-30

Family

ID=52395018

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705626QA SG11201705626QA (en) 2015-01-23 2016-01-21 Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis

Country Status (26)

Country Link
US (1) US10253028B2 (en)
EP (1) EP3247713B1 (en)
JP (1) JP6625649B2 (en)
KR (1) KR102572178B1 (en)
CN (1) CN107406452B (en)
AR (1) AR103474A1 (en)
AU (1) AU2016208528B2 (en)
BR (1) BR112017015828B1 (en)
CA (1) CA2973432C (en)
CL (1) CL2017001857A1 (en)
CO (1) CO2017007135A2 (en)
CR (1) CR20170339A (en)
DO (1) DOP2017000167A (en)
EA (1) EA032763B1 (en)
ES (1) ES2754803T3 (en)
IL (1) IL253427B (en)
MX (1) MX2017009525A (en)
MY (1) MY190895A (en)
PE (1) PE20180020A1 (en)
PH (1) PH12017501307B1 (en)
SG (1) SG11201705626QA (en)
TW (1) TWI726861B (en)
UA (1) UA120385C2 (en)
UY (1) UY36525A (en)
WO (1) WO2016116563A1 (en)
ZA (1) ZA201704586B (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706754B2 (en) * 2000-11-06 2004-03-16 The United States Of America As Represented By The Secretary Of The Army Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
EP1880791A1 (en) 2006-07-21 2008-01-23 Aleris Aluminum Koblenz GmbH Process and apparatus for laser joining two components through the use of a laminar inert gas flow coaxial to a metal filler wire
WO2008039359A2 (en) * 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
EP2123654A4 (en) * 2006-12-28 2011-05-11 Taisho Pharmaceutical Co Ltd Pyrazolopyrimidine compound
WO2008094575A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases
MY191407A (en) * 2008-01-04 2022-06-27 Intellikine Llc Certain chemical entities, compositions and methods
PL2285808T3 (en) * 2008-04-29 2014-04-30 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
RU2011137399A (en) * 2009-02-12 2013-03-20 Астеллас Фарма Инк. HETEROCYCLIC DERIVATIVE
JP5663571B2 (en) * 2009-07-02 2015-02-04 サノフイ Novel 2,3-dihydro-1H-imidazo {1,2-a} pyrimidin-5-one derivatives, their preparation and their pharmaceutical use
AU2010326268B2 (en) * 2009-12-04 2016-11-03 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
EP3527563B1 (en) * 2013-03-12 2021-09-01 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors

Also Published As

Publication number Publication date
CO2017007135A2 (en) 2017-12-15
EP3247713B1 (en) 2019-08-28
TWI726861B (en) 2021-05-11
ES2754803T3 (en) 2020-04-20
UY36525A (en) 2016-08-31
PH12017501307A1 (en) 2018-01-29
PE20180020A1 (en) 2018-01-09
KR102572178B1 (en) 2023-08-28
MY190895A (en) 2022-05-18
EA201791658A1 (en) 2017-11-30
WO2016116563A1 (en) 2016-07-28
UA120385C2 (en) 2019-11-25
US10253028B2 (en) 2019-04-09
PH12017501307B1 (en) 2018-01-29
IL253427B (en) 2019-07-31
JP6625649B2 (en) 2019-12-25
IL253427A0 (en) 2017-09-28
US20170369496A1 (en) 2017-12-28
CA2973432A1 (en) 2016-07-28
CN107406452A (en) 2017-11-28
CL2017001857A1 (en) 2018-02-16
KR20170104611A (en) 2017-09-15
AU2016208528A1 (en) 2017-07-27
BR112017015828B1 (en) 2020-02-18
EP3247713A1 (en) 2017-11-29
DOP2017000167A (en) 2017-09-15
AR103474A1 (en) 2017-05-10
AU2016208528B2 (en) 2019-02-21
CA2973432C (en) 2023-04-04
JP2018502887A (en) 2018-02-01
ZA201704586B (en) 2019-12-18
MX2017009525A (en) 2018-04-10
EA032763B1 (en) 2019-07-31
BR112017015828A2 (en) 2018-04-24
TW201632524A (en) 2016-09-16
CN107406452B (en) 2019-07-23
CR20170339A (en) 2018-01-22

Similar Documents

Publication Publication Date Title
IL266170A (en) Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
HK1258157A1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
IL246564A (en) 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases
HK1257146A1 (en) Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
HK1244787A1 (en) Novel 5 or 8-substituted imidazo [1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases
EP3107914B8 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
HK1249502A1 (en) Pyrido(3,4-d) pyrimidine derivative and pharmaceutically acceptable salt thereof
EP3215511A4 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
EP3215509A4 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
IL266305B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
HK1254809A1 (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
EP3215510A4 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en) Pyrazolo[1,5-a]pyrimidine compound
GB201802644D0 (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
IL253427B (en) Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer